XML 75 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Pay vs Performance Disclosure
 12 Months Ended
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Pay vs Performance Disclosure [Table]      
Pay vs Performance [Table Text Block]
Pay Versus Performance
 
 
As required, below is disclosure of the compensation of the Company’s Named Executive Officers, or NEOs, for the last three fiscal years calculated in accordance with the recently adopted Item 402(v) of Regulation
S-K.
Item 402(v) requires disclosure of “compensation actually paid” based on calculations that report changes in the fair value of equity awards granted in prior years, granted during the fiscal
year, and
vesting
during the fiscal year, but that do not reflect the actual amount of compensation earned or received by any of the NEOs during the fiscal year.
For information about our compensation philosophy and how we align executive compensation with our performance, please see our Compensation Discussion and Analysis.
 
Year
                               
Value of Initial Fixed $100
Investment Based on:
                
  
Summary
Compensation
Table Total for
CEO($)
     
Compensation
Actually Paid to
CEO($)
(1)(2)
     
Average
Summary
Compensation
Table Total for
non-CEO

Named
Executive
Officers($)
     
Average
Compensation
Actually Paid to
Non-CEO

Named
Executive
Officers
(1)(2)
     
Amgen Total
Shareholder
Return($)
(3)
     
Peer Group
Total
Shareholder
Return($)
(3)(4)
     
Net
Income
($M)
     
Non-GAAP

EPS($)
(5)
  
2022
      21,399,733        41,655,553        7,211,427        12,777,767        119.07        140.14        6,552        17.69  
2021
      21,721,154        17,040,728        7,358,134        5,869,521        98.87        126.48        5,893        17.10  
2020
      20,131,408        14,724,312        6,736,942        5,571,375        98.01        102.57        7,264        16.60  
 
(1)
As the valuation methods for “compensation actually paid” required by the SEC differ from those required in the Summary Compensation Table (“SCT”), the table below provides a reconciliation of SCT amounts to the Compensation Actually Paid (“CAP”) amounts in the Pay Versus Performance table for Mr. Bradway and the average SCT and CAP amounts for our other NEOs for each of the last three fiscal years. The other
non-CEO
NEOs for each of 2022, 2021, and 2020 include Messrs. Gordon, Griffith, and Santos and Dr. Reese.
Summary Compensation Table to Compensation Actually Paid Reconciliation Table
 
                  
Required Adjustments to Summary Compensation Table (“SCT”) Totals to Determine
Compensation Actually Paid (“CAP”)
         
    
Year
     
SCT
Total($)
     
SCT Value
of Stock
Awards($)
     
SCT
Value of
Option
Awards(
$)
     
Fair Value as
of Year End of
Equity Awards
Granted
During the
Year($)
     
Year-Over-Year

Increase
(Decrease) in
Fair Value as of
Year End of
Unvested
Awards Granted
in Prior Years($)
     
Increase
(Decrease)
From Prior Year
End in Fair
Value of
Awards That
Vested During
the Year($)
     
CAP Formula and
Results($)
  
                 
           
A
     
B
     
C
     
D
     
E
     
F
     
G=A-B-C+D+E+F
  
Robert A. Bradway
      2022        21,399,733        11,138,544        4,773,714        20,800,961        11,751,273        3,615,844        41,655,553  
     2021        21,721,154        11,138,622        4,773,710        13,805,997        (2,572,161 )       (1,930 )       17,040,728  
     2020        20,131,408        10,079,676        4,319,993        13,341,787        (3,546,758 )       (802,456 )       14,724,312  
Average of Other NEOs
      2022        7,211,427        3,184,719        1,364,984        5,947,522        3,219,024        949,497        12,777,767  
     2021        7,358,134        3,246,014        1,391,226        4,023,392        (640,566 )       (234,199 )       5,869,521  
     2020        6,736,942        2,834,702        1,214,968        3,752,153        (650,362 )       (217,688 )       5,571,375  
 
(2)
Stock option fair values are calculated at each measurement date using a Black-Scholes valuation model, consistent with the approach used to value the awards at the grant date. Stock option fair values as of each measurement date were determined using updated assumptions (the closing stock price of our Common Stock as of the measurement date, risk-free interest rate, expected life, expected volatility of the price of our Common Stock, and expected dividend yield) and fair value increases are primarily driven by an increase in the price of the Company’s Common Stock.
Performance unit fair values are calculated using a payout simulation model, consistent with the approach used to value the awards at the grant date. Performance unit fair values as of each measurement date were determined using updated assumptions (risk-free interest rate, volatility of the price of our Common Stock, the closing price of our Common Stock on the measurement date, volatilities of the prices of the stocks of the Reference Group (as defined in footnote 3 to the “Grant of Plan-Based Awards” table in our Executive Compensation Tables), and the correlations of returns of our Common Stock and the stocks of the Reference Group to simulate total shareholder returns and their resulting impact on the payout percentages based on the contractual terms of the performance units) and fair value increases are primarily driven by an increase in the price of the Company’s Common Stock.
 
 
(3)
Pursuant to the SEC rules, total shareholder return, or TSR, reflects an initial investment of $100 on December 31, 2019. All values assume reinvestment of the pretax value of dividends, are calculated as of December 31 of each year, and are weighted according to the respective issuers’ stock market capitalization at the beginning of each period for which a return is indicated.
(4)
The peer group for each listed fiscal year consists of the companies listed as our executive compensation benchmarking peer group in the Compensation Discussion and Analysis specific for that year. For 2020, the companies included: Allergan plc (until July 2020); Abbvie, Inc.; AstraZeneca plc; Biogen Inc.; Bristol Myers Squibb Company; Celgene Corporation (until July 2020); Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Holding AG; and Sanofi S.A.. For 2021 and 2022, the peer group included: Abbvie, Inc.; AstraZeneca plc; Biogen Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Holding AG; and Sanofi S.A.
(5)
Non-Generally
Accepted Accounting Principles, or
non-GAAP,
earnings per share for purposes of the Company selected measure is reported and reconciled in
Appendix B
.
   
Company Selected Measure Name non-GAAP, earnings per share    
Named Executive Officers, Footnote [Text Block] The other
non-CEO
NEOs for each of 2022, 2021, and 2020 include Messrs. Gordon, Griffith, and Santos and Dr. Reese. 		   
Peer Group Issuers, Footnote [Text Block] The peer group for each listed fiscal year consists of the companies listed as our executive compensation benchmarking peer group in the Compensation Discussion and Analysis specific for that year. For 2020, the companies included: Allergan plc (until July 2020); Abbvie, Inc.; AstraZeneca plc; Biogen Inc.; Bristol Myers Squibb Company; Celgene Corporation (until July 2020); Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Holding AG; and Sanofi S.A.. For 2021 and 2022, the peer group included: Abbvie, Inc.; AstraZeneca plc; Biogen Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Holding AG; and Sanofi S.A.    
PEO Total Compensation Amount $ 21,399,733 $ 21,721,154 $ 20,131,408
PEO Actually Paid Compensation Amount $ 41,655,553 17,040,728 14,724,312
Adjustment To PEO Compensation, Footnote [Text Block]
Summary Compensation Table to Compensation Actually Paid Reconciliation Table
 
                  
Required Adjustments to Summary Compensation Table (“SCT”) Totals to Determine
Compensation Actually Paid (“CAP”)
         
    
Year
     
SCT
Total($)
     
SCT Value
of Stock
Awards($)
     
SCT
Value of
Option
Awards(
$)
     
Fair Value as
of Year End of
Equity Awards
Granted
During the
Year($)
     
Year-Over-Year

Increase
(Decrease) in
Fair Value as of
Year End of
Unvested
Awards Granted
in Prior Years($)
     
Increase
(Decrease)
From Prior Year
End in Fair
Value of
Awards That
Vested During
the Year($)
     
CAP Formula and
Results($)
  
                 
           
A
     
B
     
C
     
D
     
E
     
F
     
G=A-B-C+D+E+F
  
Robert A. Bradway
      2022        21,399,733        11,138,544        4,773,714        20,800,961        11,751,273        3,615,844        41,655,553  
     2021        21,721,154        11,138,622        4,773,710        13,805,997        (2,572,161 )       (1,930 )       17,040,728  
     2020        20,131,408        10,079,676        4,319,993        13,341,787        (3,546,758 )       (802,456 )       14,724,312  
Average of Other NEOs
      2022        7,211,427        3,184,719        1,364,984        5,947,522        3,219,024        949,497        12,777,767  
     2021        7,358,134        3,246,014        1,391,226        4,023,392        (640,566 )       (234,199 )       5,869,521  
     2020        6,736,942        2,834,702        1,214,968        3,752,153        (650,362 )       (217,688 )       5,571,375  
    
Non-PEO NEO Average Total Compensation Amount $ 7,211,427 7,358,134 6,736,942
Non-PEO NEO Average Compensation Actually Paid Amount $ 12,777,767 5,869,521 5,571,375
Adjustment to Non-PEO NEO Compensation Footnote [Text Block]
Summary Compensation Table to Compensation Actually Paid Reconciliation Table
 
                  
Required Adjustments to Summary Compensation Table (“SCT”) Totals to Determine
Compensation Actually Paid (“CAP”)
         
    
Year
     
SCT
Total($)
     
SCT Value
of Stock
Awards($)
     
SCT
Value of
Option
Awards(
$)
     
Fair Value as
of Year End of
Equity Awards
Granted
During the
Year($)
     
Year-Over-Year

Increase
(Decrease) in
Fair Value as of
Year End of
Unvested
Awards Granted
in Prior Years($)
     
Increase
(Decrease)
From Prior Year
End in Fair
Value of
Awards That
Vested During
the Year($)
     
CAP Formula and
Results($)
  
                 
           
A
     
B
     
C
     
D
     
E
     
F
     
G=A-B-C+D+E+F
  
Robert A. Bradway
      2022        21,399,733        11,138,544        4,773,714        20,800,961        11,751,273        3,615,844        41,655,553  
     2021        21,721,154        11,138,622        4,773,710        13,805,997        (2,572,161 )       (1,930 )       17,040,728  
     2020        20,131,408        10,079,676        4,319,993        13,341,787        (3,546,758 )       (802,456 )       14,724,312  
Average of Other NEOs
      2022        7,211,427        3,184,719        1,364,984        5,947,522        3,219,024        949,497        12,777,767  
     2021        7,358,134        3,246,014        1,391,226        4,023,392        (640,566 )       (234,199 )       5,869,521  
     2020        6,736,942        2,834,702        1,214,968        3,752,153        (650,362 )       (217,688 )       5,571,375  
    
Compensation Actually Paid vs. Total Shareholder Return [Text Block]
(1)
   
LOGO
   
Compensation Actually Paid vs. Net Income [Text Block]
(2)
    LOGO
   
Compensation Actually Paid vs. Company Selected Measure [Text Block]
(3)
    LOGO
   
Total Shareholder Return Vs Peer Group [Text Block]
(1)
   
LOGO
   
Tabular List [Table Text Block]
2022 Performance Measures
Pursuant to Item 402(v) of
Regulation S-K,
the Compensation Committee identified the following financial and
non-financial
performance measures used in our long-term and annual incentive programs as representing the most important performance measures used to link “compensation actually paid” in 2022 to the Company’s performance.
 
•
   
Non-GAAP
earnings per share (EPS)
•
   
Non-GAAP
return on invested capital (ROIC)
•
   Total shareholder return (TSR) relative to that of the S&P 500
•
   Revenues
 
   
•
   
Non-GAAP
net income
•
   Pipeline, clinical study, and regulatory goals
•
   Environmental, social, and governance goals
 
 
    
Total Shareholder Return Amount $ 119.07 98.87 98.01
Peer Group Total Shareholder Return Amount 140.14 126.48 102.57
Net Income (Loss) $ 6,552,000,000 $ 5,893,000,000 $ 7,264,000,000
Company Selected Measure Amount 17.69 17.1 16.6
PEO Name Mr. Bradway    
Measure [Axis]: 1      
Pay vs Performance Disclosure [Table]      
Measure Name Non-GAAP earnings per share (EPS)    
Non-GAAP Measure Description [Text Block]
Non-Generally
Accepted Accounting Principles, or
non-GAAP,
earnings per share for purposes of the Company selected measure is reported and reconciled in
Appendix B
.
   
Measure [Axis]: 2      
Pay vs Performance Disclosure [Table]      
Measure Name Non-GAAP return on invested capital (ROIC)    
Measure [Axis]: 3      
Pay vs Performance Disclosure [Table]      
Measure Name Total shareholder return (TSR) relative to that of the S&P 500    
Measure [Axis]: 4      
Pay vs Performance Disclosure [Table]      
Measure Name Revenues    
Measure [Axis]: 5      
Pay vs Performance Disclosure [Table]      
Measure Name Non-GAAP net income    
Measure [Axis]: 6      
Pay vs Performance Disclosure [Table]      
Measure Name Pipeline, clinical study, and regulatory goals    
Measure [Axis]: 7      
Pay vs Performance Disclosure [Table]      
Measure Name Environmental, social, and governance goals    
PEO [Member] | SCT Value Of Stock Awards [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount $ 11,138,544 $ 11,138,622 $ 10,079,676
PEO [Member] | SCT Value Of Option Awards [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 4,773,714 4,773,710 4,319,993
PEO [Member] | Fair Value As Of Year End Of Equity Awards Granted During The Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 20,800,961 13,805,997 13,341,787
PEO [Member] | Year Over Year Increase Decrease In Fair Value As Of Year End Of Unvested Awards Granted In Prior Years [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 11,751,273 (2,572,161) (3,546,758)
PEO [Member] | Increase Decrease From Prior Year End In Fair Value Of Awards That Vested During The Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 3,615,844 (1,930) (802,456)
Non-PEO NEO [Member] | SCT Value Of Stock Awards [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 3,184,719 3,246,014 2,834,702
Non-PEO NEO [Member] | SCT Value Of Option Awards [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 1,364,984 1,391,226 1,214,968
Non-PEO NEO [Member] | Fair Value As Of Year End Of Equity Awards Granted During The Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 5,947,522 4,023,392 3,752,153
Non-PEO NEO [Member] | Year Over Year Increase Decrease In Fair Value As Of Year End Of Unvested Awards Granted In Prior Years [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 3,219,024 (640,566) (650,362)
Non-PEO NEO [Member] | Increase Decrease From Prior Year End In Fair Value Of Awards That Vested During The Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount $ 949,497 $ (234,199) $ (217,688)